335 related articles for article (PubMed ID: 20089558)
1. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma.
Antoun S; Baracos VE; Birdsell L; Escudier B; Sawyer MB
Ann Oncol; 2010 Aug; 21(8):1594-1598. PubMed ID: 20089558
[TBL] [Abstract][Full Text] [Related]
2. Body Composition by Computed Tomography as a Predictor of Toxicity in Patients With Renal Cell Carcinoma Treated With Sunitinib.
Cushen SJ; Power DG; Teo MY; MacEneaney P; Maher MM; McDermott R; O'Sullivan K; Ryan AM
Am J Clin Oncol; 2017 Feb; 40(1):47-52. PubMed ID: 24685884
[TBL] [Abstract][Full Text] [Related]
3. Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma.
Mir O; Coriat R; Blanchet B; Durand JP; Boudou-Rouquette P; Michels J; Ropert S; Vidal M; Pol S; Chaussade S; Goldwasser F
PLoS One; 2012; 7(5):e37563. PubMed ID: 22666367
[TBL] [Abstract][Full Text] [Related]
4. Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients.
Huillard O; Mir O; Peyromaure M; Tlemsani C; Giroux J; Boudou-Rouquette P; Ropert S; Delongchamps NB; Zerbib M; Goldwasser F
Br J Cancer; 2013 Mar; 108(5):1034-41. PubMed ID: 23462722
[TBL] [Abstract][Full Text] [Related]
5. Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study.
Antoun S; Birdsell L; Sawyer MB; Venner P; Escudier B; Baracos VE
J Clin Oncol; 2010 Feb; 28(6):1054-60. PubMed ID: 20085939
[TBL] [Abstract][Full Text] [Related]
6. Sarcopenic obesity: A probable risk factor for dose limiting toxicity during neo-adjuvant chemotherapy in oesophageal cancer patients.
Anandavadivelan P; Brismar TB; Nilsson M; Johar AM; Martin L
Clin Nutr; 2016 Jun; 35(3):724-30. PubMed ID: 26065721
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib-induced pancreatitis.
Amar S; Wu KJ; Tan WW
Mayo Clin Proc; 2007 Apr; 82(4):521. PubMed ID: 17418082
[No Abstract] [Full Text] [Related]
8. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
Escudier B; Lassau N; Angevin E; Soria JC; Chami L; Lamuraglia M; Zafarana E; Landreau V; Schwartz B; Brendel E; Armand JP; Robert C
Clin Cancer Res; 2007 Mar; 13(6):1801-9. PubMed ID: 17363536
[TBL] [Abstract][Full Text] [Related]
10. [Myocardial metastasis from renal cell carcinoma treated with sorafenib].
Tokuyama Y; Iwamura M; Fujita T; Sugita A; Maeyama R; Bessho H; Ishikawa W; Tabata K; Yoshida K; Baba S
Hinyokika Kiyo; 2011 Oct; 57(10):555-8. PubMed ID: 22089153
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency.
Khan G; Golshayan A; Elson P; Wood L; Garcia J; Bukowski R; Rini B
Ann Oncol; 2010 Aug; 21(8):1618-1622. PubMed ID: 20089567
[TBL] [Abstract][Full Text] [Related]
12. Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib.
Tamaskar I; Bukowski R; Elson P; Ioachimescu AG; Wood L; Dreicer R; Mekhail T; Garcia J; Rini BI
Ann Oncol; 2008 Feb; 19(2):265-8. PubMed ID: 17962201
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.
Escudier B; Szczylik C; Hutson TE; Demkow T; Staehler M; Rolland F; Negrier S; Laferriere N; Scheuring UJ; Cella D; Shah S; Bukowski RM
J Clin Oncol; 2009 Mar; 27(8):1280-9. PubMed ID: 19171708
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib in metastatic renal cell carcinoma with sarcomatoid differentiation.
Lekili M; Muezzinoglu T; Nese N; Temeltas G
J Chin Med Assoc; 2010 May; 73(5):262-4. PubMed ID: 20685594
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.
Gollob JA; Rathmell WK; Richmond TM; Marino CB; Miller EK; Grigson G; Watkins C; Gu L; Peterson BL; Wright JJ
J Clin Oncol; 2007 Aug; 25(22):3288-95. PubMed ID: 17664476
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib-induced erythema multiforme for metastatic renal cell carcinoma.
Kodaira M; Takahashi S; Takeuchi K; Yuasa T; Saotome T; Yonese J; Fukui I; Hatake K
Ann Oncol; 2010 Jul; 21(7):1563-1565. PubMed ID: 20573851
[No Abstract] [Full Text] [Related]
17. A cross-over response to sequential use of sunitinib after sorafenib in a patient with metastatic renal cell carcinoma.
Richards TM; Plowman PN; Reznek R; Ball SA
Clin Oncol (R Coll Radiol); 2009 Oct; 21(8):633-4. PubMed ID: 19380217
[No Abstract] [Full Text] [Related]
18. Characterization of tumor specimens for a targeted therapy in metastatic renal cell carcinoma patients.
Raspollini MR
Curr Oncol Rep; 2007 Sep; 9(5):331. PubMed ID: 17706159
[No Abstract] [Full Text] [Related]
19. Sorafenib rechalenge in metastatic renal cell carcinoma.
Porta C; Paglino C; Imarisio I
BJU Int; 2012 Sep; 110(6 Pt B):E235. PubMed ID: 22332769
[No Abstract] [Full Text] [Related]
20. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.
Garcia JA; Hutson TE; Elson P; Cowey CL; Gilligan T; Nemec C; Dreicer R; Bukowski RM; Rini BI
Cancer; 2010 Dec; 116(23):5383-90. PubMed ID: 20806321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
